Cover Image


Antibody Drug Conjugate Market Opportunity Analysis

出版商 KuicK Research 商品編碼 302584
出版日期 內容資訊 英文 350 Pages
商品交期: 最快1-2個工作天內
Back to Top
抗體藥物複合體(ADC)市場上機會分析 Antibody Drug Conjugate Market Opportunity Analysis
出版日期: 2014年05月01日 內容資訊: 英文 350 Pages

抗體藥物複合體(ADC),救助受以往無恰當治療方法之疾病所苦的患者,發展為特別治療層級的藥物。使用抗體醫藥品的治療,費用高是主要的課題之一。可是,由醫療經濟的觀點看來,未來中,其成本效益應該是非常高。為了實現這個,改善藥物效果是重要的,現在,許多製藥企業著重這個領域。由於brentuximab vedotin(Adcetris)及ado-trastuzumab emtansine(Kadcyla)的認證,及臨床實驗開發平台中有100個以上的抗體藥物複合體(ADC)存在,預計這個治療層級在未來將大幅成長。全球ADC市場,今後將以超越40%的年複合成長率擴大,預計2020年達到68億美元。


第1章 抗體藥物複合體的簡介

第2章 抗體藥物複合體的機制

  • 抗體藥物複合體的成分
  • 抗體藥物複合體的機制

第3章 抗體藥物複合體的必要性

第4章 抗體藥物複合體市場預測

  • 市場概要
  • 抗體藥物複合體的臨床實驗平台分析

第5章 抗體藥物複合體市場力學

  • 市場接受性
  • 應致力處理的課題
  • 未來的成長機會

第6章 抗體藥物複合體臨床實驗情形:階段及標的各適應症

  • 研究
  • 前臨床
  • 第一階段
  • 第1/2階段
  • 第二階段
  • 第2/3階段
  • 第三階段

第7章 已上市的抗體藥物複合體

第8章 競爭情形

  • ADC Therapeutics
  • Agensys
  • Ambrx
  • Amgen
  • AREVA Med
  • Bayer HealthCare
  • Genentech
  • Immunomedics
  • ImmunoGen
  • Seattle Genetics

Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.

The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.

With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.

The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.

"Antibody Drug Conjugate Market Opportunity Analysis" Report Highlights:

  • Global ADC Market Insight
  • ADC Patent Analysis
  • Orphan Status & ADC
  • Favorable Market Drivers & Key Issues to be Discussed
  • ADC Clinical Trial Insight by Phase & Target Indications
  • ADC Profiles in Report: 201
  • Majority of ADC in Preclinical Phase: 83
  • Marketed ADC Clinical Profiles

Table of Contents

1. Introduction to Antibody Drug Conjugate

2. Antibody Drug Conjugate Mechanism

  • 2.1. Components of Antibody Drug Conjugate
  • 2.2. Mechanism of Antibody Drug Conjugate

3. Why Need for Antibody Drug Conjugate?

4. Antibody Drug Conjugate Market Outlook

  • 4.1. Market Overview
  • 4.2. Anti Drug Conjugate Clinical Pipeline Analysis

5. Antibody Drug Conjugate Market Dynamics

  • 5.1. Market Acceptability Drivers
  • 5.2. Issues to be Addressed
  • 5.3. Future Growth Opportunities

6. Antibody Drug Conjugate Clinical Trial Insight by Phase & Target Indications

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Phase I
  • 6.4. Phase I/II
  • 6.5. Phase II
  • 6.6. Phase II/III
  • 6.7. Phase III

7. Marketed Antibody Drug Conjugate

8. Competitive Landscape

  • 8.1. ADC Therapeutics
  • 8.2. Agensys
  • 8.3. Ambrx
  • 8.4. Amgen
  • 8.5. AREVA Med
  • 8.6. Bayer HealthCare
  • 8.7. Genentech
  • 8.8. Immunomedics
  • 8.9. ImmunoGen
  • 8.10. Seattle Genetics

List of Figures

  • Figure 2-1: Components of Antibody Drug Conjugate
  • Figure 2-2: Mechanism of Antibody Drug Conjugate
  • Figure 4-1: Global Antibody Drug Conjugate Market (US$ Billion), 2013-2020
  • Figure 4-2: Global Adcetris Sales (Million US$), 2013 & 2020
  • Figure 4-3: Adcetris Sales in US & Europe (Million US$), 2013
  • Figure 4-4: Global Kadcyla Sales (Million US$), 2013 & 2020
  • Figure 4-5: Kadcyla Market in US & Ex US (Million US$), 2013
  • Figure 4-6: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
  • Figure 4-7: Antibody Drug Conjugate Clinical Pipeline by Phase (%)

List of Tables

  • Table 8-1: ADC Therapeutics Clinical Pipeline
  • Table 8-2: Agensys Clinical Pipeline
  • Table 8-3: Ambrx Clinical Pipeline
  • Table 8-4: Amgen Clinical Pipeline
  • Table 8-5: AREVA Med Clincal Pipeline
  • Table 8-6: Genentech Clinical Pipeline
  • Table 8-7: Immunomedics Clinical Pipeline
  • Table 8-8: ImmunoGen Clinical Pipeline
  • Table 8-9: Seattle Genetics Clinical Pipeline
Back to Top